The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11110 malaria professionals are enjoying the free benefits of MalariaWorld today


Not Open Access | The evolution and diversity of a low complexity vaccine candidate, merozoite surface protein 9 (MSP-9), in Plasmodium vivax and closely related species

October 16, 2013 - 18:46 -- NOT Open Access
Stella M. Chenet, M. Andreína Pacheco, David J. Bacon, William E. Collins, John W. Barnwell, Ananias A. Escalante
Infection, Genetics and Evolution, Volume 20, December 2013, Pages 239-248

Our findings suggest that the gene encoding MSP-9 is under purifying selection in P. vivax and closely related species.

Cinderella science

December 1, 2012 - 14:43 -- Bart G.J. Knols

The guest blog below was contributed by Prof. Matt Thomas, of Penn State University. Read more about Professor Thomas here.

Everybody would like to see the burden of malaria reduced and while there might be some disciplinary biases, most would agree that long-term sustainable management of malaria requires integrated strategies built on solid foundations of local knowledge and capacity. 
Of the broad approaches available (and by available I include potential tools somewhere along the development pipeline), vector control is clearly pivotal. This is not to diminish the importance of other technologies, such as drugs or diagnostics, but much of the recent decline in malaria can be attributed to wide-scale implementation of vector control tools such as long lasting insecticide treated bed nets (LLINs) and indoor residual insecticide sprays (IRS). Furthermore, in nearly every historical case where malaria has been substantially reduced or locally eliminated, vector control has been key. 

Human vaccine research in the European Union

November 26, 2009 - 07:35 -- Kabogo Ndegwa
Ole F. Olesen, Anna Lonnroth, Bernard Mulligan
Vaccine, Volume 27, Issue 5, 29 January 2009, Pages 640-645, doi:10.1016/j.vaccine.2008.11.064

Taken together, around 581 research groups from 52 countries are participating in the vaccine activities of FP6. This impressive number signals a new spirit of collaborative research, which will facilitate the exploitation of the immense possibilities in modern vaccinology.

Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children

November 10, 2009 - 13:33 -- Ingeborg van Schayk
Sirima SB, Tiono AB, Ouédraogo A, Diarra A, Ouédraogo AL, et al.
PLoS ONE 4(10): e7549

Our results support the promise of MSP3-LSP as a malaria vaccine candidate, both in terms of tolerability and of immunogenicity. Further assessment of the efficacy of this vaccine is recommended.


Alternative approaches to vaccine delivery

October 25, 2009 - 16:31 -- Ingeborg van Schayk
Lina Wang, Charles Ma and Ross L. Coppel
Human Vaccines, Volume 6, Issue 1, January 2010

Subunit vaccines under development for malaria utilise a limited number of approaches to delivery. 

Therefore, along with the efforts to advance the most promising vaccine formulations through the development pipeline, research is taking place into alternative methods for cheaper vaccine production and easy administration. This chapter will discuss some of these approaches, including transgenic plants and mammals as bioreactors for low cost vaccine production and alternative routes of vaccine delivery such as mucosal immunization.

Medical Treatment: 


Subscribe to RSS - vaccine